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Abstract: Several case reports have described hypopituitarism following orthohantavirus infection,
mostly following Puumala virus. The pathogenesis of this seemingly rare complication of
orthohantavirus infection remains unknown. This review explores the possible pathophysiological
mechanisms of pituitary damage due to orthohantavirus infection. In only three out of the 28 reported
cases, hypopituitarism was detected during active infection. In the remaining cases, detection of
pituitary damage was delayed, varying from two months up to thirteen months post-infection.
In these cases, hypopituitarism remained undetected during the acute phase of infection or only
occurred weeks to months post infection. Both ischemic and hemorrhagic damage of the pituitary
gland have been detected in radiographic imaging and post-mortem studies in the studied case
reports series. Ischemic damage could be caused by hypotension and/or vasospasms during the
acute phase of hemorrhagic fever with renal syndrome (HFRS) while hemorrhage could be caused
by thrombocytopenia, thrombopathy, and other known causes of coagulation disorders during
orthohantavirus infection. Also, hypophysitis due to the presence of auto-antibodies have been
suggested in the literature. In conclusion, a significant number of case reports and series describe
hypopituitarism after orthohantavirus infection. In most cases hypopituitarism was diagnosed with
a delay and therefore could very well be underreported. Clinicians should be aware of this potential
endocrine complication, with substantial morbidity, and if unrecognized, significant mortality.
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1. Introduction
Hemorrhagic fever with renal syndrome (HFRS) comprises a group of clinically similar
rodent-borne infectious diseases caused by orthohantaviruses, including Hantaan (HTNV), Dobrava
(DOBV), Seoul (SEOV), Saaremaa (SAAV), and Puumala virus (PUUV) [1]. The clinical course of
these infections is classically characterized by a triad of acute renal failure, fever, and hemorrhagic
complications. HFRS can be divided into five phases: febrile, hypotensive, oliguric, diuretic, and a
convalescent phase [2,3]. Each pathogenic orthohantavirus is carried by a specific rodent and the
demographic location of each type of HFRS corresponds to the natural habitat of this rodent species.
Generally, HTNV is mainly prevalent in Asia, whereas DOBV is circulating in the Far East and the
Balkans. PUUV generally results in a milder disease and is endemic in Scandinavia and Western
Europe, Central Europe, and Russia. With a numerous and geographically wide-spread zoonotic
reservoir, Rattus species, SEOV is the only orthohantavirus prevalent worldwide [3].
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Depending on which orthohantavirus species infects a patient, case fatality rates vary from
<1% to 15% [2,3]. Besides often observed renal complications, patients may present with extrarenal
complications in the respiratory and cardiovascular system while severe hemorrhage may also occur [4].
From the old world hantaviruses, DOBV infections are generally considered to result in the highest
percentage of hemorrhagic complications (up to 15–30%), while PUUV is known to cause nephropathia
epidemica (NE), a syndrome comparable to HFRS with a milder clinical course and mortality rates of
0.1–1% [5].
Several case reports have described hypopituitarism following orthohantavirus infection.
The pathogenesis of this complication remains unknown. Already in the 1950s, different post-mortem
studies showed pituitary damage, e.g., foci of hemorrhage and necrosis, in 58–72% of patients
with hemorrhagic fever, which are now thought to be HFRS cases [6,7]. In 1985, a study by
Lim et al. demonstrated pituitary gland atrophy on radiographic imaging in seven out of eleven
confirmed HFRS patients [8]. Later, Valtonen et al. described three fatal cases of acute NE in which
pituitary gland damage was detected during autopsy [9]. Literature about the global prevalence
of pituitary damage following HFRS is scarce, however data suggests that pituitary damage,
characterized by endocrinological disturbances including potential life-threatening Addison’s crises,
due to orthohantavirus infection is not uncommon. This review aims to explore the possible
pathophysiological mechanisms for pituitary damage in orthohantavirus infections in literature and
illustrates its clinical relevance.
2. Pathophysiology of Hypopituitarism
The pituitary gland produces hormones that control major physiological endocrine systems
in the body. The anterior pituitary gland regulates growth via the production of growth hormone,
the thyroid function through production of thyroid-stimulation hormone (TSH), the blood pressure
(via adrenocorticotropic hormone (ACTH)), and the gonadal function (via luteinizing hormone (LH)
and follicle-stimulating hormone (FSH)). In the posterior pituitary cells, the hypothalamic hormones
anti-diuretic hormone (ADH) and oxytocin are stored and subsequently released when needed [10].
Hypopituitarism is a condition in which one or more hormones are insufficiently released by
the pituitary gland [10,11]. Insufficient ACTH and TSH release can lead to an adrenal crisis or severe
hypothyroidism and can be life-threatening [11]. Primary hypopituitarism is caused by pathology of
the pituitary gland itself, secondary hypopituitarism is caused by a dysfunctional hypothalamus [11].
Most commonly, primary hypopituitarism is caused by mechanical pressure on (by tumors or edema),
or hemorrhage inside, the pituitary gland [10,12,13].
Another known cause of primary hypopituitarism is Sheehan’s syndrome where pituitary necrosis
follows postpartum blood loss [14]. During pregnancy, the pituitary enlarges for the purpose of
lactation and requires a relatively increased blood supply [15]. Hypovolemia due to postpartum
hemorrhaging may lead to insufficient blood supply to the pituitary. Other pathological processes
that might lead to pituitary damage in Sheehan’s syndrome include the presence of vasospasm;
thrombosis, potentially in the context of disseminated intravascular coagulation (DIC) or peripartum
prothrombogenic state; and hypotension [14]. Pituitary failure due to auto-immunity is a relatively
rare condition, where inflammation processes are either primarily targeted at the pituitary gland,
such as lymphocytic or granulomatous hypophysitis, or occur in systemic auto-immune diseases,
such as sarcoidosis or Crohn’s disease, and bacterial or viral infections like HIV and cytomegalovirus
infection [16]. In contrast to acute vascular damage to the pituitary gland, an autoimmune mechanism
underlying the pituitary gland problems seen post-orthohantavirus infection could explain a more
smothering clinical course. For instance, endocrine disturbances caused by auto-antibodies due to
orthohantavirus infection has been suggested in a single case report [17].
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3. Clinical Consequences of Hypopituitarism
Clinical manifestation of hypopituitarism depends on the hormones that are lacking and the
rapidity of onset [10]. An overview of clinical features of hypopituitarism is given in Table 1.
The general signs in patients with hypopituitarism are nonspecific, such as fatigue and weakness [18].
Dysfunction of the posterior pituitary gland occurs less frequently than dysfunction of the anterior
gland. However, posterior pituitary gland dysfunction causing diabetes insipidus due to anti-diuretic
hormone (ADH) deficiency does have significant clinical consequences [11,19]. Deficiency of the
growth-hormone (GH) usually precedes dysfunction of the gonadotropic axes (LH and FSH)
followed by impaired production of TSH and ACTH. Deficiencies of ACTH and TSH are potentially
life-threatening, whereas deficiencies of LH, FSH, and GH are associated with chronic morbidity [11,20].
Table 1. Clinical features of hypopituitarism [10,11,19,20].
Hormone Deficiency Signs and Symptoms
Growth hormone (GH)
Increased body fat; reduced muscle mass and strength;
reduced stamina and psychological problems, e.g., depression
or concentration loss; dyslipidemia; atherosclerosis
Luteinizing and follicle-stimulating
hormone (LH and FSH)
Sub- or infertility, loss of libido
Men: impotence; testicle atrophy; loss of facial, body, and
pubic hair; reduced muscle mass; osteoporosis
Women: a- or oligomenorrhea, dyspareunia, osteoporosis
Thyroid-stimulation hormone (TSH) Cold intolerance, weight gain, fatigue, hair loss, constipation,hoarse voice
Adrenocorticotropic hormone (ACTH) (Orthostatic) hypotension, hypoglycemia, fatigue,muscle weakness
Prolactin (PL) Postpartum failure of lactation
Antidiuretic hormone (ADH) Polydipsia and polyuria
Hypopituitarism can be adequately treated using hormone replacement therapy of end-hormones
from involved pituitary axes [11,18]. Duration of therapy depends on the reversibility of the damage to
the pituitary gland [11]. Specific attention is warranted for glucocorticoid replacement as an increase
in dosage is necessary in the case of acute stress and illness, meaning that continuous monitoring
and adjustments of hormone replacements are needed in patients with inadequate stress hormone
response [10,11].
4. Hemorrhagic Complications in Orthohantavirus Infection
It is plausible that the pituitary gland dysfunction observed post orthohantavirus infection is a
result of hemorrhagic complications seen in HFRS. Orthohantavirus infections are, like other viral
hemorrhagic fevers, associated with a triad of thrombocytopenia, endothelial cell dysfunction, and
disseminated intravascular coagulation (DIC) resulting in various hemorrhagic complications [21].
The mechanisms by which these are caused are only partially understood. Clinical observational
studies focusing on alterations in primary and secondary hemostasis during orthohantavirus disease
showed thrombocytopenia in both HFRS and New World orthohantavirus cardiopulmonary syndrome
(HCPS). A decreased plasma activity of coagulation factors II, V, VIII, IX, and X in acute HFRS patients,
prolongation of the prothrombin and activated partial thromboplastin time, increased thrombin
generation and D-dimer levels, and a decrease in ADAMTS13 activity were observed in PUUV-infected
patients [22–25]. Orthohantaviruses are able to infect endothelial cells in vitro by binding to
β3-integrins, a cell surface receptor involved in platelet function and vascular permeability [26,27].
Multiple in vitro studies investigated the role of endothelial cells in orthohantavirus infection.
Dendritic cells and macrophages produce pro-inflammatory cytokines during infection, which evoke a
changing phenotype of the endothelium towards a pro-adhesive (for immune cells) and pro-coagulant
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response during inflammation promoting a final procoagulant shift of the endothelium [28]. This causes
increased vascular permeability and enhanced recruitment of platelets on the endothelial surface [29].
Furthermore, orthohantaviruses interact with the GPIIa/IIIb receptors on the surface of
thrombocytes, which upon binding leads to increased platelet activation [30]. Thereby, a direct binding
between PUUV particles and quiescent platelets is possible [31]. In contrast to other hemorrhagic fever
viruses, which decrease maturation and stimulate apoptosis of megakaryocytes, orthohantaviruses
stimulate HLA expression of megakaryocytes in vitro, making them potential targets for cytotoxic
lymphocytes, which on itself potentially decreases the production of platelets [32,33]. Both loss of
activated platelets and a decreased platelet production in orthohantavirus infection could result
in a decrease in number of circulating platelets and thereby interact with primary hemostasis.
In vitro, orthohantavirus infection of endothelial cells directly leads to an increase of tissue factor
and subsequent thrombin generation and a decrease of fibrinolysis, resulting in a clear procoagulant
state [31] while a suppression of Thrombospondin 1 and an increase of tissue plasminogen activator
have also been described [34,35]. In line with in vivo data, an adequate response in secondary
hemostasis could very well also be hampered during orthohantavirus infection.
5. Clinical Characteristics of Hypopituitarism Due to Orthohantavirus Infection
However, clear bleeding of the pituitary gland does not seem to be the underlying mechanism in
all of the reported cases of hypopituitarism after orthohantavirus infection. Direct pituitary damage
due to orthohantavirus has been identified and published in 28 patients in 11 case-reports and
case-series [9,17,36–44]. Thus far, impaired function of the posterior lobe of the pituitary has not
been described. An overview and summary of the data retrieved from literature is provided in Table 2.
PUUV infection was reported most frequently (14/28 cases) [9,17,38–40,43,44]. While one case
report discussed DOBV infection [36], in 14 cases (two originating from Korea [37,41] and twelve
originating from Serbia [42,43]), a specific orthohantavirus type was not mentioned since diagnosis was
made via serology detecting multiple orthohantaviruses. However, given the geographical distribution
of the orthohantavirus serotypes, the two cases originating from Korea might concern HNTV or
SEOV, while cases originating from Serbia might concern PUUV, SEOV, or DOBV. It remains unclear
whether one of the orthohantaviruses specifically predisposes for this complication. In four cases, the
hypopituitarism was detected during active infection [36,37,39,44]. In three of these cases, reasons to
suspect an endocrine disturbance during infection were impaired recovery despite improving clinical
and biochemical parameters of infection and detection of hypothyroidism during routine thyroid
testing [36,37,39]. In the fourth case, the rationale for endocrinal testing during admission was not
provided [44]. Radiographic imaging eventually revealed either an atrophic or enlarged pituitary
gland with signs of hemorrhage and/or necrosis in all these cases.
In the remaining cases, detection of pituitary damage was delayed varying from a few months
to thirteen years after infection [17,38,40–43]. These patients presented with signs of endocrine
disturbances after recovery from orthohantavirus infection. Most frequently reported symptoms were
persistent fatigue despite improving renal function or improving hyperlipidemia [43]. Some patients
were diagnosed with hypogonadism [38,40,43]. In one case, therapy-resistant ventricular tachycardia
led to the discovery of hypopituitarism and subsequent hypothyroidism 13 years after having HFRS,
which eventually resolved after hormonal replacement therapy with glucocorticoids and thyroid
hormones [41]. Furthermore, one patient suffered initially from hypogonadism and hypothyroidism
six months after acute infection. Another six months later this patient developed polydipsia and
polyuria due to diabetes insipidus [17].
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Table 2. Summary of the 28 cases of post orthohantivurs panhypopituitarism reported in literature. NE-IFAT: nephropathia epidemica indirect immunofluorescence
assay test.
Serotype Country No. Diagnostics Endocrine Disturbances Time toDetection Duration Outcome Ref
Puumala Finland 1 NE-IFAT titre Panhypopituarism 5 years NR Survived Forslund et al., 1992 [38]
Puumala Sweden 1 Specific Puumala IgM and IgG Panhypopituitarism 6 months NR Survived Settergen et al., 1992 [40]
NR Korea 1 Serologic antibody testing Panhypopituitarism Day 20 a NR Survived Suh et al., 1994 [37]
Puumala Finland 4 NR NR - - Deceased Valtonen et al., 1995 b [9]
NR Korea 1 NR Panhypopituitarism 13 years NR Survived Kim et al., 2001 [41]
Puumala b
Puumala
Puumala
Finland
Finland
Finland
1
1
1
Serologic antibody testing
Serologic antibody testing
Serologic antibody testing
NR
Panhypopituitarism
Panhypopituitarism
-
5 months
Day 7 a
-
NR
NR
Deceased
Survived
Survived
Hautala et al., 2002 [44]
NR
Puumala
Puumala
Serbia
Serbia
Serbia
1
1
1
Serologic antibody testing
Serologic antibody testing
Serologic antibody testing
Panhypopituitarism
Panhypopituitarism
ACTH, FSH, LH and GH
1.5 years
2 years
2 years
NR
NR
NR
Survived
Survived
Survived
Pekic et al., 2005 [42]
NR
NR
NR
NR
Serbia
Serbia
Serbia
Serbia
3
2
1
5
Indirect immunofluorescent assay
Indirect immunofluorescent assay
Indirect immunofluorescent assay
Indirect immunofluorescent assay
GH
FSH, LH
ACTH
≥4 axes
>6 months
>6 months
>6 months
0.5–11 yrs
NR
NR
NR
NR
Survived
Survived
Survived
Survived
Stojanovic et al., 2008 [42]
Puumala Austria 1 Specific Puumala IgM Panhypopituitarism Acute a 5 months Survived Jost et al., 2009 [39]
Dobrova Turkey 1 Serologic antibody testing Panhypopituitarism Day 19 a 16 months Survived Sariguzel et al., 2010 [36]
Puumala Finland 1 Specific Puumala IgM and IgG TSH, FSH, LH, ADH 6 months Ongoing Survived Tarvainen et al., 2016 [17]
a Hormonal disturbances detected during acute infection; b Post-mortem study revealing pituitary hemorrhage. NR: not reported.
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In twelve cases, pituitary damage was confirmed with either a computerized tomography (CT) or
Magnetic resonance imaging (MRI) scan, showing atrophy of the pituitary gland [17,43,44], or even
an empty sella [38,43], but an enlarged pituitary with signs of hemorrhage was also noted in some
cases [36,39,44]. One patient had a normal aspect of the pituitary gland on the CT scan [40].
All patients experienced acute renal failure. Of these patients sixteen patients required
hemodialysis or -filtration [36,37,42,43]. In four cases the clinical course was also complicated by
extrarenal manifestations, such as myocardial infarction, pancreatitis, acute respiratory distress
syndrome, gastro-intestinal bleeding, DIC, and septic shock [36,40,43].
Lastly, in five cases, pituitary damage was revealed during postmortem examination [9,44]. Both
necrotic and hemorrhagic areas were present in the pituitary. In the case of Hautala et al., granulocyte
infiltration of the gland was observed [44]. In the cases of Valtonen et al., all patients suffered from
diffuse intravascular coagulation [9].
All surviving patients were successfully treated with hormonal replacement. The duration of
therapy was not reported in most cases. In two cases, replacement therapy was only required for
several months, possibly indicating reversible damage [36,39].
6. Pathophysiology of Orthohantavirus Associated Hypopituitarism
The exact pathophysiological mechanism leading to hypopituitarism after an orthohantavirus
infection remains to be elucidated; however, there are several theories that can explain this
phenomenon. The mechanism in hypopituitarism following orthohantavirus infection was suggested
to be analogous to Sheehan’s syndrome after postpartum fluxus, as the acute phase of orthohantavirus
infection can be accompanied by hypotension [43,44]. In this theory, necrosis is caused by insufficient
vascular supply of the pituitary gland due to hypotension, potentially combined by vasospasm due
to septic shock. This is supported by the autopsy findings of Steer et al., which showed 21 out of
36 patients with HFRS who died during the hypotensive phase and all of 28 patients who died in
the oliguric phase had pituitary gland damage [6]. A postmortem study by Hullinghorst and Steer
from the 1950s did not detect occlusion of the pituitary vasculature of patients who died due to
orthohantavirus infection [45]. This finding makes vasospasms resulting from hypotension during
or due to orthohantavirus infection a possible cause of pituitary gland necrosis. Proving this theory,
however, is difficult as vasospasms cannot be assessed with histopathologic features.
Pituitary damage in orthohantavirus infection could also be caused by a hemorrhage. A study of
Stojanovic et al. on hypopituitarism after PUUV infection showed patients with hypopituitarism had
significantly lower platelet levels during acute infection compared to patients with normal pituitary
function after infection, suggesting an important role of thrombocytopenia in the pathogenesis of
hypopituitarism after orthohantavirus infection [42]. Indeed, foci of hemorrhage were found in the
pituitary gland after orthohantavirus infection [9]. An association between hypopituitarism and the
severity of infection, mainly determined by the duration of the oliguric phase, has been suggested [8].
It seems that thrombocytopenia and uremia give a generalized risk for hemorrhage since an increased
uremia level on its own causes thrombocytopathy. However, bleeding complications in hantavirus
infection are most likely the result of a more complex interaction between the virus, endothelial cell,
and immune system. The question why hemorrhage specifically occurs in the pituitary gland remains
unanswered. Jost et al. suggested the existence of hypophysitis in orthohantavirus infection [39].
Additional evidence comes from the study of Hautala et al. in which PUUV orthohantavirus has
been isolated from stromal cells and vascular endothelial cells of the pituitary gland [44]. The latter
could lead to endothelial damage and dysfunction, making the pituitary gland more prone to
vascular damage. However, this result might also suggest direct damage of pituitary cells due
to infection. Tarvainen et al., who reported on hypopituitarism six months after acute infection,
suggested hypopituitarism to be an auto-immune reaction triggered by PUUV infection as MRI
findings compatible with hypophysitis sequela and elevated thyroid peroxidase antibodies were
found [17].
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One would expect the occurrence and the extent of pituitary damage to be related to the clinical
severity of the acute infection. However, a Sheenan-like phenomenon would be the result of persistent
hypotension, something hardly observed in PUUV, which usually has a mild and favorable clinical
course. Furthermore, a retrospective study of Stojanovic et al., which evaluated the prevalence of
hypopituitarism after HFRS, reported a prevalence of 13% in a median of two years after recovery,
showing the relatively high prevalence of this complication [42]. The duration of the oliguric phase
and occurrence of complications are used to determine the clinical severity of hemorrhagic fever [8].
Severity of pituitary damage is suggested to be related to the stage of the disease. However, Steer et al.
demonstrated that 58% of their patients who died during the hypotensive stage had mild pituitary
necrosis, whereas 100% of the patients who died during oliguric phase had severe pituitary necrosis [6].
Furthermore, there were also specific cases only showing isolated pituitary necrosis without signs of
multi organ failure. On the other hand, thrombopoietin, procoagulant activity, coagulation variables,
and platelet indices, e.g., mean platelet volume, are shown not to be predictive of the severity of renal
insufficiency and hypotension due to PUUV infection. This further questions the correlation between
pituitary damage and the severity of infection [46]. However, thrombocytopenia has shown to be
associated with the severity of inflammation, e.g., expressed as a C-reactive protein (CRP), and severity
of capillary leakage in acute PUUV infection [47]. Pituitary gland damage (e.g., due to orthohantavirus
infection) can be visualized using a CT or MRI. However, one can question whether radiographic
imaging observations correspond to the presence and severity of endocrine disturbances. In a clinical
study by Lim et al., patients obtained follow-up CT scans during the acute infection and convalescent
phase of infection [8]. The severity of pituitary atrophy or necrosis on imaging did not correspond to
the level of hormone disturbances in laboratory testing. Thereby, Partanen et al. re-evaluated a cohort
of patients four to eight years after acute NE. All patients underwent MRI examinations during acute
infection [48]. This study did not reveal any significant hormonal disturbances. Even though abnormal
hormonal laboratory testing was found in some patients, these were deviations from reference intervals
due to secondary factors, e.g., obesity or use of medication.
7. Discussion
Case reports and series in the past two decades have been associating orthohantavirus infection
with hypopituitarism. The fact that patients initially present with nonspecific symptoms or even
subclinical disease potentially contributes to delayed diagnosis. Less specific abnormalities in the
gonadal and thyroid axis were reported retrospectively in 30 of 54 patients during acute NE, suggesting
a significant problem [49]. However, one should keep in mind that a dysbalanced hormonal axis in
these 30 patients was not necessary be the result of hypopituitarism. The exact pathophysiological
mechanisms leading to hypopituitarism during or following orthohantavirus infection remains
unknown. While also preexisting endocrinological pathology could be detected once a patient presents
to the hospital with HFRS as described in [50]. We have summarized potential underlying mechanisms
in Figure 1. Autopsy cases and radiographic imaging have confirmed both necrotic and hemorrhagic
damage of the pituitary gland [6–8]. However, long term follow-up did not always confirm the
persistency of hormonal abnormalities [49]. The group of cases reporting late-onset hypopituitarism
did not take other confounders into account. Orthohantavirus can lead to ischemic, necrotic, and
hemorrhagic damage of the pituitary gland. The precise pathophysiological mechanism leading to
this damage is to date unclear. However, several mechanisms have been explored in literature and are
summarized in Figure 1. Ischemic damage could be caused by hypotension and/or vasospasms, and
hemorrhagic damage could be caused by thrombocytopenia and thrombopathy. Also, the presence
of hypophysitis and auto-antibodies post orthohantavirus infection have been suggested. Since all
data thus far relies on observational studies with low numbers of patients, it is impossible to make
strong recommendations. However, there seems to be a significant association between pituitary
gland dysfunction and hantavirus infection. Several questions need to be answered. For instance,
in vitro or ex vivo infection with hantavirus of pituitary gland cells could confirm the potential
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tropism of orthohantavirus for the pituitary gland. Meanwhile, for discriminating between vascular
or auto-immune mechanisms, an animal model could be of interest. In conclusion, hypopituitarism
after orthohantavirus infection is frequently diagnosed with a delay and is possibly under-reported or
-detected. Clinicians should be more aware of this complication as endocrine disturbances can severely
affect a patient’s wellbeing.
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